Peptide API CMO Market: By Product Type, By Therapeutic area, By End User and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Peptide API CMO Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Peptide Generic API, Peptide NCEs), By Therapeutic area (Oncology, Cardiovascular Disorders, Metabolic Disorders, CNS Disorders, Respiratory Disorders, Gastrointestinal Disorders, Anti-infective, Dermatology, Renal Disorders, Others), By End User (Pharmaceutical Companies, Biopharmaceutical Companies) and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Peptide API CMO Market was valued at US$ 1,756.0 million in 2023 and is expected to grow at a 7.2% CAGR from 2024 to 2029. The pharmaceutical companies are driving the growth of the peptide API CMO market by seeking reliable partners to meet their growing manufacturing needs. One key driver is the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has spurred the development of peptide-based therapeutics.

According to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality worldwide, with an estimated 10 million deaths in 2020. As the demand for effective treatments for these diseases continues to rise, pharmaceutical companies are increasingly turning to CMOs to fulfil their peptide API manufacturing requirements.Peptide API CMO Market

Moreover, the increasing complexity and regulatory scrutiny associated with peptide drug development pose challenges for pharmaceutical companies, driving them to seek external expertise and support. CMOs with a track record of successfully navigating regulatory requirements and delivering high-quality peptide APIs are in high demand as pharmaceutical companies strive to bring innovative therapies to market efficiently. In conclusion, the market is driven the rising prevalence of chronic diseases and the need for external expertise and support in drug development. As the demand for peptide-based therapeutics continues to grow, the market is poised for significant expansion in the coming years.  

Key Developments:

  • In August 2023, ScinoPharm Taiwan, Ltd. announced robust performance in its API (Active Pharmaceutical Ingredients) business segment and demonstrated flexible growth in the preparations market.
  • In January 2023, CordenPharma has secured a significant milestone by finalizing a multi-year manufacturing agreement, effective from 2023, for the production of a high-volume peptide at its CordenPharma Colorado facility. This partnership, expected to encompass a value of approximately US$ 1 billion based on projected production volumes throughout the contract's duration, will facilitate the introduction of an innovative peptide into the market.
  • In September 2022, Bachem Group has issued an ad hoc announcement in compliance with Art. 53 LR of the Swiss stock exchange SIX, revealing the signing of two significant contracts for the provision of large volumes of peptides.

summary download arrow Download Free Sample

Global Peptide Api Cmo Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7.2%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Peptide API CMO Market Dynamics

In recent years, the demand for peptide drugs has surged, leading to a significant expansion in the peptide API Contract Manufacturing Organization (CMO) market. This growth is propelled by several key supply-side drivers that are reshaping the landscape of peptide manufacturing. One crucial driver is the increasing complexity of peptide APIs and the specialized expertise required for their production. Peptide drugs are becoming more intricate in their molecular structures, often requiring advanced synthesis techniques and specialized equipment for manufacturing. As a result, pharmaceutical companies are turning to CMOs with extensive experience and capabilities in peptide synthesis to meet their manufacturing needs.

Furthermore, the shift towards personalized medicine and the development of targeted peptide therapies for various diseases such as cancer, diabetes, and autoimmune disorders is fueling demand for specialized peptide manufacturing services. As pharmaceutical companies focus on developing tailored treatments for specific patient populations, they rely on CMOs with the expertise to produce custom peptide APIs efficiently. The significant driver is the increasing adoption of outsourcing by pharmaceutical companies to streamline their operations and reduce costs. Outsourcing peptide manufacturing to CMOs allows pharmaceutical companies to leverage the expertise and infrastructure of specialized manufacturers without investing in expensive equipment and facilities themselves.

Global Peptide Api Cmo Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 1,756.0 million

Market CAGR

7.2%

By Product Type

  • Peptide Generic API
  • Peptide NCEs

By Therapeutic area

  • Oncology
  • Cardiovascular Disorders
  • Metabolic Disorders
  • CNS Disorders
  • Respiratory Disorders
  • Gastrointestinal Disorders
  • Anti-infectives
  • Dermatology
  • Renal Disorders
  • Others

By End User

  • Pharmaceutical Companies
  • Biopharmaceutical Companies

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The peptide api cmo market report provides granular level information about the market size, regional market share, historic market (2019 to 2023) and forecast (2024 to 2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup's details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The peptide API CMO market was valued at US$ 1,756.0 million in 2023 and is expected to grow at a 7.2% CAGR from 2024 to 2030.

Expansion of peptide therapeutic applications and advancements in peptide delivery technologies is expected to provide opportunities to the market players in the market growth over the forecast period.

The leading players in the global Peptide API CMO Market are ScinoPharm Taiwan, Ltd., Corden Pharma International, Bachem AG, Biopeptek Pharmaceuticals LLC., Hybio Pharmaceutical Co., Ltd., Chinese Peptide Company, AmbioPharm, Inc., Teva Pharmaceutical Industries Ltd. PolyPeptide Group, Chemi S.p.A.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Peptide Api Cmo Market Introduction 
2.1.Global Peptide Api Cmo Market  - Taxonomy
2.2.Global Peptide Api Cmo Market  - Definitions
2.2.1.Product Type 
2.2.2.Therapeutic area
2.2.3.End Users
2.2.4.Region
3. Global Peptide Api Cmo Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Peptide Api Cmo Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Peptide Api Cmo Market  By Product Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Peptide Generic API
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Peptide NCEs
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6. Global Peptide Api Cmo Market  By Therapeutic area, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Oncology
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Cardiovascular Disorders
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Metabolic Disorders
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. CNS Disorders
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Respiratory Disorders
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Gastrointestinal Disorders
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Anti-infectives
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
6.8. Dermatology
6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.8.3. Market Opportunity Analysis 
6.9. Renal Disorders
6.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.9.3. Market Opportunity Analysis 
6.10. Others
6.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.10.3. Market Opportunity Analysis 
7. Global Peptide Api Cmo Market  By End Users, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Pharmaceutical Companies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Biopharmaceutical Companies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8. Global Peptide Api Cmo Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Peptide Api Cmo Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Product Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Peptide Generic API
9.1.2.Peptide NCEs
9.2.  Therapeutic area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oncology
9.2.2.Cardiovascular Disorders
9.2.3.Metabolic Disorders
9.2.4.CNS Disorders
9.2.5.Respiratory Disorders
9.2.6.Gastrointestinal Disorders
9.2.7.Anti-infectives
9.2.8.Dermatology
9.2.9.Renal Disorders
9.2.10.Others
9.3.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Pharmaceutical Companies
9.3.2.Biopharmaceutical Companies
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Peptide Api Cmo Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Peptide Generic API
10.1.2.Peptide NCEs
10.2.  Therapeutic area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oncology
10.2.2.Cardiovascular Disorders
10.2.3.Metabolic Disorders
10.2.4.CNS Disorders
10.2.5.Respiratory Disorders
10.2.6.Gastrointestinal Disorders
10.2.7.Anti-infectives
10.2.8.Dermatology
10.2.9.Renal Disorders
10.2.10.Others
10.3.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Pharmaceutical Companies
10.3.2.Biopharmaceutical Companies
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Peptide Api Cmo Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Peptide Generic API
11.1.2.Peptide NCEs
11.2.  Therapeutic area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oncology
11.2.2.Cardiovascular Disorders
11.2.3.Metabolic Disorders
11.2.4.CNS Disorders
11.2.5.Respiratory Disorders
11.2.6.Gastrointestinal Disorders
11.2.7.Anti-infectives
11.2.8.Dermatology
11.2.9.Renal Disorders
11.2.10.Others
11.3.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Pharmaceutical Companies
11.3.2.Biopharmaceutical Companies
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Peptide Api Cmo Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Peptide Generic API
12.1.2.Peptide NCEs
12.2.  Therapeutic area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oncology
12.2.2.Cardiovascular Disorders
12.2.3.Metabolic Disorders
12.2.4.CNS Disorders
12.2.5.Respiratory Disorders
12.2.6.Gastrointestinal Disorders
12.2.7.Anti-infectives
12.2.8.Dermatology
12.2.9.Renal Disorders
12.2.10.Others
12.3.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Pharmaceutical Companies
12.3.2.Biopharmaceutical Companies
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Peptide Api Cmo Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Peptide Generic API
13.1.2.Peptide NCEs
13.2.  Therapeutic area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oncology
13.2.2.Cardiovascular Disorders
13.2.3.Metabolic Disorders
13.2.4.CNS Disorders
13.2.5.Respiratory Disorders
13.2.6.Gastrointestinal Disorders
13.2.7.Anti-infectives
13.2.8.Dermatology
13.2.9.Renal Disorders
13.2.10.Others
13.3.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Pharmaceutical Companies
13.3.2.Biopharmaceutical Companies
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.ScinoPharm Taiwan, Ltd.
14.2.2.Corden Pharma International
14.2.3.Bachem AG
14.2.4.Biopeptek Pharmaceuticals LLC.
14.2.5.Hybio Pharmaceutical Co., Ltd.
14.2.6.Chinese Peptide Company
14.2.7.AmbioPharm, Inc.
14.2.8.Teva Pharmaceutical Industries Ltd.
14.2.9.PolyPeptide Group
14.2.10.Chemi S.p.A.
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • ScinoPharm Taiwan, Ltd.
  • Corden Pharma International
  • Bachem AG
  • Biopeptek Pharmaceuticals LLC.
  • Hybio Pharmaceutical Co., Ltd.
  • Chinese Peptide Company
  • AmbioPharm, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • PolyPeptide Group
  • Chemi S.p.A.

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market